187 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
25 Mar 24
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
4:05pm
to fund our planned operations for at least the next twelve months.
Research and Development Expenses (R&D) Expenses – R&D expenses decreased by $3.5 … million in fiscal 2023 as compared to fiscal 2022. The Company reduced research and development costs when it received FDA approval of PEDMARK®
8-K
EX-99.1
if79lgchibch6savmr34
6 Nov 23
Fennec Pharmaceuticals Announces Third Quarter 2023
7:38pm
8-K/A
EX-99.1
f9tcntp6j
7 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:51am
8-K
EX-99.1
43sic7ot cd2sy0dh6
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:58am
8-K
EX-99.1
m3ispe
4 Aug 23
Fennec Pharmaceuticals Announces Second Quarter 2023
10:57am